Compass Therapeutics, Inc. (CMPX): who owns it and who trades it
As of Nov 16, 2026, CMPX insiders reported 4 purchases worth $96.8K in the last 12 months. The largest buyer was Neil Lerner (Chief Accounting Officer), with $49.6K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Compass Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CMPX
216 funds and institutions reported CMPX shares worth $364M at the end of Q2 2026, about 92% of the company. The largest holder is Tang Capital Management LLC with 10.0%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Tang Capital Management LLC | 17.99M | 9.99% | $39.4M | +7% |
| Orbimed Advisors LLC | 15.22M | 8.45% | $33.3M | No change |
| Montanova Capital, LLC | 14.10M | 7.83% | $30.9M | -1% |
| BlackRock, Inc. | 11.28M | 6.26% | $24.7M | +19% |
| State Street Corp | 9.95M | 5.53% | $21.8M | +49% |
| Enavate Sciences Gp, LLC | 7.79M | 4.32% | $17.1M | No change |
| Vivo Capital, LLC | 7.76M | 4.31% | $17M | -19% |
| Vanguard Capital Management LLC | 6.12M | 3.40% | $13.4M | +1% |
| Palo Alto Investors LP | 5.83M | 3.24% | $12.8M | +285% |
| Millennium Management LLC | 4.71M | 2.62% | $10.3M | +457% |
| Geode Capital Management, LLC | 3.82M | 2.12% | $8.4M | +7% |
| Vanguard Portfolio Management LLC | 3.77M | 2.09% | $8.3M | +248% |
| Qube Research & Technologies Ltd | 3.69M | 2.05% | $8.1M | +45% |
| Blue Owl Capital Holdings LP | 3.62M | 2.01% | $7.9M | +23% |
| Citadel Advisors LLC | 3.57M | 1.98% | $7.8M | +395% |
| Goldman Sachs Group Inc | 3.53M | 1.96% | $7.7M | +77% |
| Rock Springs Capital Management LP | 3.52M | 1.96% | $7.7M | +7% |
| AQR Capital Management LLC | 3.51M | 1.95% | $7.7M | +1651% |
| Birchview Capital, LP | 1.68M | 0.93% | $3.7M | +14% |
| Kingdon Capital Management, L.l.c. | 1.40M | 0.78% | $3.1M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CMPX insiders reported $96.8K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Neil Lerner | Chief Accounting Officer | Purchase | 20,000 | $0.92 | $18.4K | Form 4 |
| Sep 24, 2026 | Neil Lerner | Chief Accounting Officer | Purchase | 2,500 | $1.14 | $2.8K | Form 4 |
| Apr 29, 2026 | Neil Lerner | Chief Accounting Officer | Purchase | 15,000 | $1.89 | $28.4K | Form 4 |
| Apr 29, 2026 | Jonathan Anderman | General Counsel | Purchase | 25,000 | $1.89 | $47.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Neil Lerner | Chief Accounting Officer | $49.6K | – | Oct 1, 2026 |
| Jonathan Anderman | General Counsel | $47.2K | – | Apr 29, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CMPX short interest
Very high short interest. 22.6% of CMPX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 31%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 40.79M CMPX shares were sold short, 22.6% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 2.15M shares, buying them all back would take about 18.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 40.79M | 22.65% | -3% | 2.15M | 18.9 |
| Oct 15, 2026 | 41.84M | 23.24% | +4% | 7.50M | 5.6 |
| Sep 30, 2026 | 40.36M | 22.41% | -3% | 6.45M | 6.3 |
| Sep 15, 2026 | 41.65M | 23.13% | +2% | 2.61M | 16.0 |
| Aug 31, 2026 | 40.79M | 22.65% | +1% | 2.36M | 17.3 |
| Aug 14, 2026 | 40.20M | 22.32% | +1% | 4.11M | 9.8 |
| Jul 31, 2026 | 39.87M | 22.14% | +1% | 2.26M | 17.6 |
| Jul 15, 2026 | 39.30M | 21.82% | +6% | 2.51M | 15.7 |
| Jun 30, 2026 | 37.14M | 20.62% | +14% | 4.18M | 8.9 |
| Jun 15, 2026 | 32.50M | 18.05% | -2% | 3.43M | 9.5 |
| May 29, 2026 | 33.27M | 18.47% | +7% | 5.19M | 6.4 |
| May 15, 2026 | 31.02M | 17.23% | +2% | 7.63M | 4.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Compass Therapeutics company events
Compass Therapeutics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Sep 22, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 1, 2026AnnouncementShared information with investors. Filing
- Jun 23, 2026RulesChanged its bylaws or articles. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 27, 2026AnnouncementThe Company announced data for COMPANION-002, the Company’s Phase 2/3 randomized trial of tovecimig (formerly CTX-009) in combination with paclitaxel in patients with advanced BTC. The study enrolled 168 adult patients, randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or… Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 6, 2026AnnouncementOf this Current Report, to the extent required, is incorporated into this Item 2.02 by reference. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Compass Therapeutics financials
Famous investors that hold CMPX
4 of the 50 well-known investors we track reported holding CMPX in their latest 13F filing. The largest position is Israel Englander's, worth $4.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 4.69M | $4.9M | 0.0% | -1% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.14M | $2.2M | 0.0% | -40% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 1.95M | $2M | 0.0% | +40% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 289,033 | $301K | 0.0% | -58% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CMPX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.3% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.3% |
Questions about Compass Therapeutics, Inc. (CMPX) stock
Who owns the most CMPX stock?
The largest reported owner of Compass Therapeutics, Inc. (CMPX) is Tang Capital Management LLC, with 10.0% of the company. In total, 216 funds and institutions reported holding CMPX at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are CMPX insiders buying or selling?
In the last 12 months, CMPX insiders reported 4 open-market purchases worth $96.8K and no sales. The latest trade was on Oct 1, 2026. See every trade.
What is the short interest in CMPX?
As of Oct 30, 2026, 40.79M CMPX shares were sold short, 22.6% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 2.15M shares, buying them all back would take about 18.9 trading days (days to cover). See the history.
Which famous investors hold CMPX?
4 of the 50 well-known investors we track reported CMPX in their latest 13F filing, including Israel Englander, Ken Griffin, Ken Fisher. The largest position is worth $4.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.